Diagnosing Parkinson's in the earliest stages before symptoms become serious is a major challenge in medicine, and digital health company PreciseDx thinks it may have a solution to the problem.
as well as the phase 2b LUMA study in early-stage Parkinson’s. LIGHTHOUSE will be dropped in order to focus attention on LUMA, which will read out much sooner and will now have its protocol ...